Tillman Gerngross (Adagio)
Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next?
Less than a year into its existence, serial biotech entrepreneur Tillman Gerngross’ antibody play Adagio has raced ahead into a pivotal trial for its lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
